Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$44.25 -0.4%	$38.61	$30.04 ▼ $63.68	$3.82B	1.75	1.78 million shs	3.05 million shs
DNA Ginkgo Bioworks	$8.53 -0.5%	$7.78	$5.00 ▼ $17.46	$501.62M	1.25	1.46 million shs	987,316 shs
DNLI Denali Therapeutics	$13.89 -1.4%	$14.32	$10.57 ▼ $33.33	$2.02B	1.32	1.12 million shs	1.53 million shs
KRYS Krystal Biotech	$132.46 +0.3%	$143.35	$122.80 ▼ $219.34	$3.83B	0.65	286,027 shs	691,210 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-0.41%	+6.99%	+19.63%	+7.35%	-26.94%
DNA Ginkgo Bioworks	-0.50%	-4.54%	+15.09%	+16.81%	-59.64%
DNLI Denali Therapeutics	-1.42%	-4.54%	+1.46%	-3.74%	-32.64%
KRYS Krystal Biotech	+0.28%	-3.36%	+4.56%	-29.22%	-23.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	3.2831 of 5 stars	4.2	2.0	0.0	2.7	2.5	0.6
DNA Ginkgo Bioworks	0.8538 of 5 stars	0.8	1.0	0.0	3.1	2.5	1.3
DNLI Denali Therapeutics	4.3697 of 5 stars	4.5	1.0	4.7	2.6	2.5	0.0
KRYS Krystal Biotech	4.4578 of 5 stars	3.5	1.0	4.7	2.7	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.47	Hold	$69.53	57.14% Upside
DNA Ginkgo Bioworks	1.67	Reduce	$5.77	-32.42% Downside
DNLI Denali Therapeutics	3.06	Buy	$33.71	142.72% Upside
KRYS Krystal Biotech	3.00	Buy	$211.13	59.39% Upside

Current Analyst Ratings Breakdown

Latest DNA, CRSP, KRYS, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/9/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/8/2025	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$53.00 ➝ $47.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $81.00
5/7/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $82.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	102.42	N/A	N/A	$22.64 per share	1.95
DNA Ginkgo Bioworks	$227.04M	2.20	N/A	N/A	$13.17 per share	0.65
DNLI Denali Therapeutics	$330.53M	6.11	N/A	N/A	$8.53 per share	1.63
KRYS Krystal Biotech	$290.52M	13.18	$4.64 per share	28.56	$32.90 per share	4.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
DNA Ginkgo Bioworks	-$547.03M	-$9.16	N/A	N/A	N/A	-198.84%	-52.35%	-27.14%	8/14/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.16	31.84	13.14	N/A	37.17%	14.64%	13.28%	8/4/2025 (Estimated)

Latest DNA, CRSP, KRYS, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
DNA Ginkgo Bioworks	N/A	4.88	4.88
DNLI Denali Therapeutics	N/A	9.56	9.56
KRYS Krystal Biotech	N/A	9.65	9.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
DNA Ginkgo Bioworks	78.63%
DNLI Denali Therapeutics	92.92%
KRYS Krystal Biotech	86.29%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.30%
DNA Ginkgo Bioworks	9.72%
DNLI Denali Therapeutics	12.50%
KRYS Krystal Biotech	13.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.65 million	Optionable
DNA Ginkgo Bioworks	640	58.53 million	52.84 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.94 million	Optionable

DNA, CRSP, KRYS, and DNLI Headlines

Recent News About These Companies

Janney Montgomery Scott LLC Has $8.28 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

June 21 at 3:44 AM | marketbeat.com

2KRYS : $100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

June 20 at 5:02 PM | benzinga.com

Roman Butler Fullerton & Co. Buys New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)

June 18 at 6:11 AM | marketbeat.com

Is Abeona Therapeutics' Zevaskyn Worth $3.1m Per Treatment, Or Will Krystal Biotech Remain The Market Leader?

June 16, 2025 | seekingalpha.com

Krystal Biotech (NASDAQ:KRYS) & VectivBio (NASDAQ:VECT) Financial Comparison

June 16, 2025 | americanbankingnews.com

Handelsbanken Fonder AB Sells 11,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Krystal Biotech FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Brokers Offer Predictions for Krystal Biotech FY2026 Earnings

June 10, 2025 | marketbeat.com

Hennion & Walsh Asset Management Inc. Sells 3,473 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

June 6, 2025 | marketbeat.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by GAMMA Investing LLC

June 6, 2025 | marketbeat.com

Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report?

June 5, 2025 | zacks.com

Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | finance.yahoo.com

Implied Volatility Surging for Krystal Biotech Stock Options

June 2, 2025 | msn.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 23,197 Krystal Biotech, Inc. (NASDAQ:KRYS)

June 2, 2025 | marketbeat.com

Squarepoint Ops LLC Has $1.50 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

June 1, 2025 | marketbeat.com

Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Brokerages

June 1, 2025 | marketbeat.com

Krystal Biotech Enters Oversold Territory (KRYS)

May 31, 2025 | nasdaq.com

Krystal Biotech (NASDAQ:KRYS) Hits New 12-Month Low - Here's Why

May 28, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 14,743 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

May 28, 2025 | marketbeat.com

Bank of America Corp DE Has $11.88 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

May 25, 2025 | marketbeat.com

Palisades Investment Partners LLC Purchases 3,436 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA, CRSP, KRYS, and DNLI Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$44.25 -0.18 (-0.41%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$44.26 +0.02 (+0.03%)

As of 06/20/2025 07:52 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Ginkgo Bioworks NYSE:DNA

$8.53 -0.05 (-0.55%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$8.37 -0.16 (-1.91%)

As of 06/20/2025 07:52 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$13.89 -0.20 (-1.42%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$13.99 +0.10 (+0.69%)

As of 06/20/2025 05:08 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$132.46 +0.37 (+0.28%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$132.52 +0.06 (+0.05%)

As of 06/20/2025 06:07 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time